This committee advises on the broad range of human health and societal issues raised by the development and use, and potential misuse of genetic technologies.
This act passed by the United States Senate prevents health insurers and employers from using genetic information to determine eligibility, set premiums, or hire and fire people.
This committee works to reduce morbidity and mortality in newborns and children who are at risk for heritable disorders by recommending a Uniform Screening Panel for newborn screening.
This Michigan act is to protect and promote public health and provide for the prevention and control of diseases and disabilities.
The Metabolic Clinic provides lifelong follow-up and treatment for individuals diagnosed with inborn errors of metabolism through newborn screening.
The NBS Endocrine Follow-Up Program is located at the University of Michigan C.S. Mott Children’s Hospital Division of Endocrinology which coordinates follow-up for babies who test positive for congenital hypothyroidism and congenital adrenal hyperplasia (CAH).
This public health program, required by Michigan Law, helps find babies with rare but serious medical conditions that require early treatment.
This overview of Michigan’s EHDI Program explains the process of identification, intervention, and follow-up for newborns with congenital hearing loss.
This Morbidity and Mortality Report from the CDC focuses on ensuring and improving the quality of genetic laboratory services and public health outcomes.
From the CDC these laboratory guidelines provide standards to ensure quality biochemical genetic testing and newborn screening. This site contains the laws, regulations, publications and history of these standards.
